+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Drug Conjugates Market Report 2022-2032

  • PDF Icon

    Report

  • 434 Pages
  • November 2022
  • Region: Global
  • Visiongain
  • ID: 5806054
The Antibody Drug Conjugates Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Effective and Targeted Medicines are Gaining Traction

Effective and targeted medicines are urgently required in the worldwide health emergency brought on by the (COVID-19) pandemic. Since antibody therapies are relatively simple to develop in comparison to conventional small-molecular medications and are just as precise as vaccines in focusing on the SARS-CoV-2 coronavirus, they have received a lot of attention recently. Seven SARS-CoV-2 antibodies having 3D structures that have been stored in the Protein Data Bank are reviewed (PDB). The possibility of five 3D antibody structures linked to the SARS-CoV spike (S) protein to neutralize SARS-CoV-2 is also assessed. These antibodies' interactions with the S protein receptor-binding domain (RBD) are contrasted with the interactions between complexes including ACE2 and the RBD.

Antibody-Drug Conjugates (ADCs) For Cancer Therapy for Drawing Attention from All over the World

Significant traction has been observed for this market owing to the abundance of newly developed antibody-drug conjugates (ADCs) for cancer therapy, drawing attention from all over the world. Even though finding an appropriate mix of an antibody, a linker, and a payload for an ADC can be quite difficult, as of September 2021, 11 ADCs had received FDA clearance, with eight of those being approved in 2017. In 2020, many mergers and partnerships were recorded in the ADC sector despite the COVID-19 pandemic, demonstrating that Big Pharma is highly interested in this therapeutic approach.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the antibody drug conjugates market evolving?
  • What is driving and restraining the antibody drug conjugates market?
  • How will each antibody drug conjugates submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • How will the market shares for each antibody drug conjugates submarket develop from 2022 to 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading antibody drug conjugates markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the antibody drug conjugates projects for these leading companies?
  • How will the industry evolve during the period between 2020 and 2032? What are the implications of antibody drug conjugates projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the antibody drug conjugates market?
  • Where is the antibody drug conjugates market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the antibody drug conjugates market today, and over the next 10 years:

  • Our 434-page report provides 184 tables and 242 charts /graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the antibody drug conjugates market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising antibody drug conjugates prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Market Segment by Payload Type

  • MMAE
  • DM4
  • Camptothecin
  • DM1
  • MMAF
  • Other Payload Type

Market Segment by Technology

  • Cleavable Linkers
  • Non-Cleavable Linkers
  • Other Technology

Market Segment by Linker Type

  • VC
  • Sulfo-SPDB
  • SMCC
  • Other Linker Type
  • VA
  • Hydrazone

Market Segment by Target Antigen

  • CD30
  • HER2
  • CD22
  • CD33
  • Other Target Antigen

Market Segment by Application

  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
  • Other Application
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • Russia
  • United Kingdom
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

South America

  • Brazil
  • Mexico
  • Rest of South America

Middle East & Africa

  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa
The report also includes profiles and for some of the leading companies in the Antibody Drug Conjugates Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

  • AbbVie Inc. Company
  • Astellas Pharma Inc.
  • Bayer AG
  • Celldex Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • ImmunoGen, Inc.
  • Lantheus Holdings, Inc.
  • Lonza Group AG
  • Merck KGaA
  • Mersana Therapeutics Inc.
  • Pfizer Inc.
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
Overall world revenue for Antibody Drug Conjugates Market, 2022 to 2032 in terms of value the market will surpass US$4,182 million in 2022, this work calculates. We predict strong revenue growth through to 2032. this work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Antibody Drug Conjugates Market, 2022 to 2032 report help you?

In summary, this 430+ page report provides you with the following knowledge:
  • Revenue forecasts to 2032 for Antibody Drug Conjugates Market, 2022 to 2032 Market, with forecasts by payload type, technology, linker type, target antigen, application, and company size, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Antibody Drug Conjugates Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, Russia, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Antibody Drug Conjugates Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Antibody Drug Conjugates Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antibody Drug Conjugates Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
2.1 Geographical Snapshot: Global Antibody Drug Conjugates Market
2.2 Technology Segment: Market Attractiveness Index
2.3 Payload Type Segment: Market Attractiveness Index
2.4 Target Antigen Segment: Market Attractiveness Index
2.5 Linker Type Segment: Market Attractiveness Index
2.6 Application Segment: Market Attractiveness Index
3 Market Overview
3.1 Key Findings
3.2 ADCs Market
3.2.1 FDA Approved Antibody Drug Conjugates
3.3 Supply Chain
3.4 Value Chain
3.5 Cold chain
3.6 Recent Trends/ Developments
3.7 Market Dynamics
3.7.1 Market Driving Factors
3.7.2 Market Restraining Factors
3.7.3 Market Opportunities
3.8 COVID-19 Impact Analysis
3.9 Porter’s Five Forces Analysis
3.9.1 Bargaining Power of Suppliers (High)
3.9.2 Bargaining Power of Buyers (Moderate)
3.9.3 Competitive Rivalry in the Market (High)
3.9.4 Threat from Substitutes (Low)
3.9.5 Threat of New Entrants (Low)
3.10 PESTLE Analysis
3.10.1 Political
3.10.2 Economical
3.10.3 Social
3.10.4 Technological
3.10.5 Legal
3.10.6 Environmental
4 Global Antibody Drug Conjugates Market Analysis
4.1 Key Findings
4.2 Global Market Outlook
4.3 Region Segment Growth Prospects
4.4 Global Antibody Drug Conjugates Market Share by Region, 2022 & 2032
4.5 Global Antibody Drug Conjugates Market Share Forecast
4.5.1 Pre-COVID-19 Market Scenario
4.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
4.6 Global Pharma Contract Sales Market by Region Size Estimation and Forecast
4.6.1 Pre-COVID-19 Market Scenario
4.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
5 Global Antibody Drug Conjugates Market Analysis by Technology
5.1 Key Findings
5.2 Global Technology Market Outlook
5.3 Global Antibody Drug Conjugates by Technology Market Attractiveness Index
5.4 Regional Market Size Estimation and Forecast
5.5 Cleavable Linkers
5.5.1 Global Cleavable Linkers Market Forecast
5.5.2 Global Cleavable Linkers Market Forecast by Region
5.6 Non-Cleavable Linkers
5.6.1 Global Non-Cleavable Linkers Market Forecast
5.6.2 Global Non-Cleavable Linkers Market Forecast by Region
5.7 Other Technology
5.7.1 Global Other Technology Market Forecast
5.7.2 Global Other Technology Market Forecast by Region
6 Global Antibody Drug Conjugates Market Analysis by Payload Type
6.1 Key Findings
6.2 Global Payload Type Market Outlook
6.3 Global Antibody Drug Conjugates by Payload Type Market Attractiveness Index
6.4 Global Antibody Drug Conjugates Market by Payload Type
6.5 MMAE
6.5.1 Global MMAE Market Forecast
6.5.2 Global MMAE Market Forecast by Region
6.6 DM4
6.6.1 Global DM4 Market Forecast
6.6.2 Global DM4 Market Forecast by Region
6.7 Camptothecin
6.7.1 Global Camptothecin Market Forecast
6.7.2 Global Camptothecin Market Forecast by Region
6.8 DM1
6.8.1 Global DM1 Market
6.8.2 Global DM1 Market Forecast by Region
6.9 MMAF
6.9.1 Global MMAF Market Forecast
6.9.2 Global MMAF Market Forecast by Region
6.10 Other Payload Type
6.10.1 Global Other Payload Type Market Forecast
6.10.2 Global Other Payload Type Market Forecast by Region
7 Global Antibody Drug Conjugates Market Analysis by Target Antigen
7.1 Key Findings
7.2 Global Target Antigen Market Outlook
7.3 Global Antibody Drug Conjugates by Target Antigen Market Attractiveness Index
7.4 Global Antibody Drug Conjugates Market by Target Antigen
7.5 CD30
7.5.1 Global CD30 Market Forecast
7.5.2 Global CD30 Market Forecast by Region
7.6 HER2
7.6.1 Global HER2 Market Forecast
7.6.2 Global HER2 Market Forecast by Region
7.7 CD22
7.7.1 Global CD22 Market Forecast
7.7.2 Global CD22 Market Forecast by Region
7.8 CD33
7.8.1 Global CD33 Market Forecast
7.8.2 Global CD33 Market Forecast by Region
7.9 Other Target Antigen
7.9.1 Global Other Target Antigen Market Forecast
7.9.2 Global Other Target Antigen Market Forecast by Region
8 Global Antibody Drug Conjugates Market Analysis by Linker Type
8.1 Key Findings
8.2 Global Linker Type Market Outlook
8.3 Global Antibody Drug Conjugates by Linker Type Market Attractiveness Index
8.4 Global Antibody Drug Conjugates Market by Linker Type
8.5 VC
8.5.1 Global VC Market Forecast
8.5.2 Global VC Market by Region
8.6 Sulfo-SPDB
8.6.1 Global Sulfo-SPDB Market Forecast
8.6.2 Global Sulfo-SPDB Market by Region
8.7 SMCC Market
8.7.1 Global SMCC Market Forecast
8.7.2 Global SMCC Market by Region
8.8 VA
8.8.1 Global VA Market Forecast
8.8.2 Global VA Market by Region
8.9 Hydrazone
8.9.1 Global Hydrazone Market Forecast
8.9.2 Global Hydrazone Market by Region
8.10 Other Linker Type
8.10.1 Global Other Linker Type Market Forecast
8.10.2 Global Other Linker Type Market by Region
9 Global Antibody Drug Conjugates Market Analysis by Application
9.1 Key Findings
9.2 Global Application Market Outlook
9.3 Global Antibody Drug Conjugates by Application Market Attractiveness Index
9.4 Global Antibody Drug Conjugates Market by Application
9.5 Blood Cancer
9.5.1 Global Blood Cancer Market Forecast
9.5.2 Global Blood Cancer Market by Region
9.6 Breast Cancer
9.6.1 Global Breast Cancer Market Forecast
9.6.2 Global Breast Cancer Market by Region
9.7 Ovarian Cancer
9.7.1 Global Ovarian Cancer Market Forecast
9.7.2 Global Ovarian Cancer Market by Region
9.8 Lung Cancer
9.8.1 Global Lung Cancer Market Forecast
9.8.2 Global Lung Cancer Market by Region
9.9 Brain Tumor
9.9.1 Global Brain Tumor Market Forecast
9.9.2 Global Brain Tumor Market by Region
9.10 Other Application
9.10.1 Global Other Application Market Forecast
9.10.2 Global Other Application Market by Region
10 North America Antibody Drug Conjugates Market Analysis
10.1 Key Findings
10.2 The Global Antibody Drug Market is predominated by North America
10.3 North America Antibody Drug Conjugates Market Attractiveness Index
10.4 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Value
10.5 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
10.6 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
10.7 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
10.8 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
10.9 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
10.10 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Application
10.11 U.S.
10.11.1 U.S. Antibody Drug Conjugates Market by Value
10.12 Canada
10.12.1 Canada Antibody Drug Conjugates Market by Value
11 Europe Antibody Drug Conjugates Market Analysis
11.1 Key Findings
11.2 Europe Antibody Drug Conjugates Market Attractiveness Index
11.3 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Value
11.4 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Country
11.5 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
11.6 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
11.7 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
11.8 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
11.9 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Application
11.10 Germany
11.10.1 Germany Antibody Drug Conjugates Market by Value
11.11 U.K.
11.11.1 U.K. Antibody Drug Conjugates Market by Value
11.12 France
11.12.1 France Antibody Drug Conjugates Market by Value
11.13 Italy
11.13.1 Italy Antibody Drug Conjugates Market by Value
11.14 Russia
11.14.1 Russia Antibody Drug Conjugates Market by Value
11.15 Rest of Europe
11.15.1 Rest of Europe Antibody Drug Conjugates Market by Value
12 Asia-Pacific Antibody Drug Conjugates Market Analysis
12.1 Key Findings
12.2 Asia-Pacific Antibody Drug Conjugates Market Attractiveness Index
12.3 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Value
12.4 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Country
12.5 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
12.6 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
12.7 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
12.8 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
12.9 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Application
12.10 China
12.10.1 China Antibody Drug Conjugates Market by Value
12.11 India
12.11.1 India Antibody Drug Conjugates Market by Value
12.12 Japan
12.12.1 Japan Antibody Drug Conjugates Market by Value
12.13 South Korea
12.13.1 South Korea Antibody Drug Conjugates Market by Value
12.14 Australia
12.14.1 Australia Antibody Drug Conjugates Market by Value
12.15 Rest of Asia-Pacific
12.15.1 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value
13 Middle East & Africa Antibody Drug Conjugates Market Analysis
13.1 Key Findings
13.2 Middle East & Africa Antibody Drug Conjugates Market Attractiveness Index
13.3 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Value
13.4 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Country
13.5 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
13.6 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
13.7 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
13.8 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
13.9 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Application
13.10 South Africa
13.10.1 South Africa Antibody Drug Conjugates Market by Value
13.11 Saudi Arabia
13.11.1 Saudi Arabia Antibody Drug Conjugates Market by Value
13.12 U.A.E.
13.12.1 U. A.E. Antibody Drug Conjugates Market by Value
13.13 Rest of Middle East & Africa
13.13.1 Rest of Middle East & Africa Antibody Drug Conjugates Market by Value
14 South America Antibody Drug Conjugates Market Analysis
14.1 Key Findings
14.2 South America Antibody Drug Conjugates Market Attractiveness Index
14.3 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Value
14.4 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
14.5 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
14.6 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
14.7 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
14.8 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
14.9 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Application
14.10 Brazil
14.10.1 Brazil Antibody Drug Conjugates Market by Value
14.11 Mexico
14.11.1 Mexico Antibody Drug Conjugates Market by Value
14.12 Rest of South America
14.12.1 Rest of South America Antibody Drug Conjugates Market by Value
15 Competitive Landscape
15.1 Company Share Analysis
15.2 Key Business Strategy Analysis- Acquisition
15.3 Key Business Strategy Analysis- Agreement
15.4 Key Business Strategy Analysis- Collaboration
15.5 Key Business Strategy Analysis- Development
15.6 Key Business Strategy Analysis- Expansion
15.7 Key Business Strategy Analysis- Investment
15.8 Key Business Strategy Analysis- Merger
15.9 Key Business Strategy Analysis- New Product Launch
15.10 Key Business Strategy Analysis- Partnership
16 Company Profiles
16.1 Abbvie Inc. Company
16.1.1 Company Snapshot
16.1.2 Company Overview
16.1.3 Financial Analysis
16.1.4 Product Benchmarking
16.1.5 Strategic Outlook
16.2 Astellas Pharma Inc.
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Financial Analysis
16.2.4 Product Benchmarking
16.2.5 Strategic Outlook
16.3 Bayer AG
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.4 Product Benchmarking
16.3.5 Strategic Outlook
16.4 Celldex Therapeutics, Inc.
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.4 Product Benchmarking
16.4.5 Strategic Outlook
16.5 Genentech, Inc.
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Product Benchmarking
16.5.4 Strategic Outlook
16.6 ImmunoGen, Inc.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.4 Product Benchmarking
16.6.5 Strategic Outlook
16.7 Gilead Sciences, Inc.
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.4 Product Benchmarking
16.7.5 Strategic Outlook
16.8 Lonza Group AG
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.4 Product Benchmarking
16.8.5 Strategic Outlook
16.9 Mersana Therapeutics Inc.
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Financial Analysis
16.9.4 Product Benchmarking
16.9.5 Strategic Outlook
16.10 Takeda Pharmaceutical Company Limited
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.4 Product Benchmarking
16.10.5 Strategic Outlook
16.11 Pfizer Inc.
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.4 Product Benchmarking
16.11.5 Strategic Outlook
16.12 F. Hoffmann-La Roche Ltd
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Financial Analysis
16.12.4 Product Benchmarking
16.12.5 Strategic Outlook
16.13 Lantheus Holdings, Inc.
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.4 Product Benchmarking
16.13.5 Strategic Outlook
16.14 Seagen Inc.
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.4 Product Benchmarking
16.14.5 Strategic Outlook
16.15 Merck KGaA
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Financial Analysis
16.15.4 Product Benchmarking
16.15.5 Strategic Outlook
17 Conclusion and Recommendations
17.1 Concluding Remarks from
17.2 Recommendations for Market Players

Companies Mentioned

  • AbbVie Inc. Company
  • Astellas Pharma Inc.
  • Bayer AG
  • Celldex Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • ImmunoGen, Inc.
  • Lantheus Holdings, Inc.
  • Lonza Group AG
  • Merck KGaA
  • Mersana Therapeutics Inc.
  • Pfizer Inc.
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
  • Abgenomics International Inc.
  • Abzena Plc
  • Adc Biotechnology Ltd.
  • Affinicon Aps
  • Agensys, Inc.
  • Ambrx Inc.
  • Amgen Inc.
  • Antikor Biopharma Ltd.
  • Astellas Pharma U.S. Inc.
  • AstraZeneca Plc
  • Bayer Ag
  • Bionavigen
  • Bioss Antibodies
  • Biotecnol
  • Biotest Ag
  • Biotest Pharmaceuticals
  • Bristol Myers Squibb
  • Bristol-Myers Squibb Co.
  • Catalent Pharma Solutions
  • Celldex Therapeutics Inc.
  • Celltrion
  • Centrose
  • Concortis Biotherapeutics
  • Creative Biolabs
  • Cytomx Therapeutics Inc.
  • Daiichi Sankyo Co. Ltd
  • Dalton Pharma Services
  • Eli Lilly And Co
  • Esperance Pharmaceuticals Inc.
  • F. Hoffmann-La-Roche Ag (Roche)
  • Formation Biologics
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Heidelberg Pharma GmBH
  • Immunomedics Inc.
  • Lonza Pharma & Biotech
  • MabPlex
  • Mersana Therapeutics Inc.
  • Millennium Pharmaceuticals Inc. (Now Takeda Oncology)
  • Millipore Sigma
  • Minakem High Potent
  • Morphosys Ag
  • Nbe Therapeutics
  • Oxford Biotherapeutics
  • Pfizer Inc.
  • Philogen Spa
  • Pierre Fabre
  • Progenics Pharmaceuticals Inc.
  • Seattle Genetics Inc.
  • Sevion Therapeutics
  • Sorrento Therapeutics Inc
  • Sutro Biopharma Inc.
  • Synthon
  • Synthon Bv
  • Viventia Biotechnologies Inc.
  • Zhejiang Medicine Co. Ltd.
  • Association of British Pharmaceutical Industry (ABPI)
  • Central Drugs Standard Control Organization (CDSCO)
  • Department of Health and Family Welfare
  • Development and Reform Commission (NDRC)
  • South American Commission
  • South American Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Indian Drug Manufacturer's Association (IDMA)
  • International Society of Pharmaceutical Engineering (IPSE)
  • Korea Food and Drug Administration (KFDA)
  • Korea Pharmaceutical Manufacturer's Association (KPMA)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicines Manufacturing Industry Partnership (MMIP)
  • Ministry of Health (MOH)
  • Ministry of Health, Labor and Welfare (MHLW)
  • Ministry of Industry and Information Technology (MIIT)
  • Pharmaceutical and Medical Devices Agency (PMDA)
  • World Health Organization (WHO)